Drug Profile

AMA 003

Alternative Names: AMA-003

Latest Information Update: 18 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amarna Therapeutics
Class Gene therapies
Mechanism of Action Gene transference; RNA interference; Vascular endothelial growth factors expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Jul 2022 Discontinued for Wet age-related macular degeneration in Netherlands (unspecified route) (Amarna Therapeutics pipeline, July 2022)
12 Jul 2022 Early research in Multiple sclerosis in Netherlands (Parenteral) before July 2022 (Amarna Therapeutics pipeline, July 2022)
21 Aug 2019 Early research in Wet age-related macular degeneration in Netherlands (Amarna Therapeutics pipeline, August 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com